PharmaCorp Rx Stock

PharmaCorp Rx Equity

The The Equity of PharmaCorp Rx (PCRX.V) as of Sep 5, 2026 is 30.34 M CAD. In the previous year, The Equity was 2.27 M CAD — a change of 1,234.20% (higher).

Equity

30.34 MCAD

YoY

1,234.20%

Last updated:

In 2026, PharmaCorp Rx's equity was 30.34 M CAD, a 1,234.20% increase from the 2.27 M CAD equity in the previous year.

The PharmaCorp Rx Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
974,200.00 CAD
Jan 1, 2022
2.72 M CAD
Jan 1, 2023
2.27 M CAD
Jan 1, 2024
30.34 M CAD
The PharmaCorp Rx Equity history
YEAREquityYoY
30.34 MCAD+1,234.20%
2.27 MCAD-16.29%
2.72 MCAD+178.89%
974,200.00CAD—
Access this data via the Eulerpool API
Get Free API Key

PharmaCorp Rx Stock analysis

What does PharmaCorp Rx do? PharmaCorp Rx is one of the most popular companies on Eulerpool.

Equity Details

Analyzing PharmaCorp Rx's Equity

PharmaCorp Rx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding PharmaCorp Rx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating PharmaCorp Rx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

PharmaCorp Rx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in PharmaCorp Rx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about PharmaCorp Rx stock

The Equity of PharmaCorp Rx is 30.34 M CAD in 2026.

The Equity of PharmaCorp Rx changed from 2.27 M CAD to 30.34 M CAD, representing a 1,234.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity PharmaCorp Rx since 2006 – with annual values, charts, and detailed analysis.

The Equity's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's PharmaCorp Rx historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — PharmaCorp Rx

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — PharmaCorp Rx